Many Contingencies To Face in Readying H1N1 Influenza Vaccines

2009 ◽  
Vol 4 (10) ◽  
pp. 445-447
Author(s):  
Jeffrey L. Fox
Keyword(s):  
H1n1 Influenza ◽  
Influenza Vaccines

scholarly journals Time for T? Thoughts about the 2009 novel H1N1 influenza outbreak and the role of T cell epitopes in the next generation of influenza vaccines

2010 ◽  
Vol 6 (2) ◽  
pp. 157-163 ◽  
Author(s):  
Anne S. De Groot ◽  
Elizabeth McClaine ◽  
Lenny Moise ◽  
William Martin
Keyword(s):  
T Cell ◽  
H1n1 Influenza ◽  
Influenza Vaccines ◽  
T Cell Epitopes ◽  
Next Generation ◽  
Influenza Outbreak ◽  
Novel H1n1 Influenza

scholarly journals Study of Neuraminidase-Inhibiting Antibodies in Clinical Trials of Live Influenza Vaccines

Antibodies ◽  
2020 ◽  
Vol 9 (2) ◽  
pp. 20
Author(s):  
Yulia Desheva ◽  
Tatiana Smolonogina ◽  
Svetlana Donina ◽  
Larisa Rudenko
Keyword(s):  
Immune Response ◽  
Clinical Trials ◽  
Immune Responses ◽  
Influenza Infection ◽  
H1n1 Influenza ◽  
Antibody Responses ◽  
Influenza Vaccines ◽  
Statistical Relationship ◽  
Serum Samples ◽  
H5n1 Influenza

Background: Currently, the immunogenicity of influenza vaccines is assessed by detecting an increase of hemagglutination inhibition (HI) antibodies. As neuraminidase (NA)-based immunity may be significant in protecting against influenza infection, detection of neuraminidase inhibiting (NI) antibodies may improve the assessment of the immunogenicity of influenza vaccines. Methods: We investigated the immune response to NA in people after immunization with live influenza vaccines (LAIVs). A number of A/H7NX or A/H6NX viruses were used to detect NI antibodies, using an enzyme-linked lectin assay (ELLA). Results: Seasonal LAIV immunization stimulated an increase in NI antibodies not only to homologous A/H1N1 influenza, but also to A/H1N1pdm09 and A/H5N1 influenza. After A/17/California/09/38 (H1N1) pdm09 LAIV vaccination, there was no statistical relationship between post-vaccinated antibody seroconversion and two surface glycoproteins in serum samples obtained from the same individuals (p = 0.24). Vaccination with LAIV of H5N2, H2N2, H7N3, and H7N9 subtypes led to 7%–29.6% NI antibody seroconversions in the absence of HI antibody conversions. There was relatively low coordination of hemagglutinin (HA) and NA antibody responses (r = 0.24–0.59). Conclusions: The previously noted autonomy for HI and NI immune responses was confirmed when assessing the immunogenicity of LAIVs. Combining the traditional HI test with the detection of NI antibodies can provide a more complete assessment of LAIV immunogenicity.

scholarly journals Modelling the risk-benefit impact of H1N1 influenza vaccines

2013 ◽  
Vol 23 (4) ◽  
pp. 674-678 ◽  
Author(s):  
L. D. Phillips ◽  
B. Fasolo ◽  
N. Zafiropoulous ◽  
H.-G. Eichler ◽  
F. Ehmann ◽  
...  
Keyword(s):  
H1n1 Influenza ◽  
Influenza Vaccines

scholarly journals Assessment of Parental Report for 2009–2010 Seasonal and Monovalent H1N1 Influenza Vaccines among Children in the Emergency Department or Hospital

2012 ◽  
Vol 12 (1) ◽  
pp. 36-42 ◽  
Author(s):  
Katherine A. Poehling ◽  
Lauren Vannoy ◽  
Laney S. Light ◽  
Cynthia K. Suerken ◽  
Beverly M. Snively ◽  
...  
Keyword(s):  
Emergency Department ◽  
H1n1 Influenza ◽  
Influenza Vaccines ◽  
Parental Report

Enhancing the reproducibility of serological methods used to evaluate immunogenicity of pandemic H1N1 influenza vaccines—An effective EU regulatory approach

Vaccine ◽  
2012 ◽  
Vol 30 (27) ◽  
pp. 4113-4122 ◽  
Author(s):  
Ralf Wagner ◽  
Constanze Göpfert ◽  
Joanna Hammann ◽  
Britta Neumann ◽  
John Wood ◽  
...  
Keyword(s):  
H1n1 Influenza ◽  
Influenza Vaccines ◽  
Pandemic H1n1 ◽  
Pandemic H1n1 Influenza ◽  
Regulatory Approach

2009 H1N1 influenza vaccines in pregnant women: The French Pharmacovigilance survey

Vaccine ◽  
2011 ◽  
Vol 29 (7) ◽  
pp. 1357-1358 ◽  
Author(s):  
I. Lacroix ◽  
C. Damase-Michel ◽  
C. Kreft-Jais ◽  
A. Castot ◽  
J.L. Montastruc
Keyword(s):  
Pregnant Women ◽  
H1n1 Influenza ◽  
Influenza Vaccines ◽  
2009 H1n1

scholarly journals “World in motion” – emulsion adjuvants rising to meet the pandemic challenges

npj Vaccines ◽  
2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Derek T. O’Hagan ◽  
Robbert van der Most ◽  
Rushit N. Lodaya ◽  
Margherita Coccia ◽  
Giuseppe Lofano
Keyword(s):  
Immune Responses ◽  
Plasma Cells ◽  
Influenza Pandemic ◽  
H1n1 Influenza ◽  
T Cell Response ◽  
Influenza Vaccines ◽  
Vaccine Adjuvants ◽  
Immunological Responses ◽  
2009 H1n1 ◽  
Human Immunity

AbstractEmulsion adjuvants such as MF59 and AS03 have been used for more than two decades as key components of licensed vaccines, with over 100 million doses administered to diverse populations in more than 30 countries. Substantial clinical experience of effectiveness and a well-established safety profile, along with the ease of manufacturing have established emulsion adjuvants as one of the leading platforms for the development of pandemic vaccines. Emulsion adjuvants allow for antigen dose sparing, more rapid immune responses, and enhanced quality and quantity of adaptive immune responses. The mechanisms of enhancement of immune responses are well defined and typically characterized by the creation of an “immunocompetent environment” at the site of injection, followed by the induction of strong and long-lasting germinal center responses in the draining lymph nodes. As a result, emulsion adjuvants induce distinct immunological responses, with a mixed Th1/Th2 T cell response, long-lived plasma cells, an expanded repertoire of memory B cells, and high titers of cross-neutralizing polyfunctional antibodies against viral variants. Because of these various properties, emulsion adjuvants were included in pandemic influenza vaccines deployed during the 2009 H1N1 influenza pandemic, are still included in seasonal influenza vaccines, and are currently at the forefront of the development of vaccines against emerging SARS-CoV-2 pandemic variants. Here, we comprehensively review emulsion adjuvants, discuss their mechanism of action, and highlight their profile as a benchmark for the development of additional vaccine adjuvants and as a valuable tool to allow further investigations of the general principles of human immunity.

Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: Population-based case–control study

Vaccine ◽  
2011 ◽  
Vol 29 (45) ◽  
pp. 7975-7981 ◽  
Author(s):  
Salaheddin Mahmud ◽  
Gregory Hammond ◽  
Lawrence Elliott ◽  
Tim Hilderman ◽  
Carol Kurbis ◽  
...  
Keyword(s):  
Case Control Study ◽  
H1n1 Influenza ◽  
Population Based ◽  
Case Control ◽  
Influenza Vaccines ◽  
Pandemic H1n1 ◽  
Pandemic H1n1 Influenza ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document